Cryobiopsy raised diagnostic yield for peripheral lung lesions, with more moderate bleeding

Design

International open-label, parallel-group randomised trial (Cryo-RCT), six centres

Population

627 patients with peripheral pulmonary lesions up to 30 mm seen on radial EBUS

Primary outcome

Histology-based diagnostic yield

Effect

Overall 83% vs 75% (difference 8.9%, 95% CI 2.8 to 15.0); moderate bleeding 38% vs 19%

In an open-label trial across six centres in Japan, Malaysia, South Korea and Taiwan, 627 patients with peripheral pulmonary lesions up to 30 mm seen on radial endobronchial ultrasound were randomised to stand-alone cryobiopsy (1 to 3 specimens) or conventional sampling with forceps or needles (aiming for five or more specimens). The primary endpoint was histology-based diagnostic yield.

In the prespecified subgroup of adjacent-to or eccentric lesions, yield was 77% with cryobiopsy and 65% with conventional sampling (difference 12.4%, 95% CI 2.8 to 22.0). Overall it was 83% (262 of 314) vs 75% (233 of 311), a difference of 8.9% (95% CI 2.8 to 15.0). Moderate bleeding was twice as common with cryobiopsy (38% vs 19%), while severe bleeding was uncommon in both (1%). Pneumothorax occurred in 2% vs under 1%, with chest-tube drainage in five patients, all in the cryobiopsy group. Serious adverse events were 2% in each group.

The trial was open-label and used radial ultrasound guidance, which not every Indian centre has. Single-use cryoprobes add cost. The benefit is greatest when the probe sits beside, rather than inside, the lesion.

• Use radial endobronchial ultrasound to judge probe-lesion position; cryobiopsy helped most with adjacent or eccentric lesions.
• Plan for more moderate bleeding and have bronchoscopic control measures ready.
• Counsel patients about a small increased pneumothorax risk.
• Check cryoprobe availability and cost before changing your sampling approach.

Why it matters

It gives randomised evidence that a different sampling tool can lift the success of lung nodule diagnosis.

Don't overread it

The trial was open-label; the abstract does not report effect on cancer detection or patient outcomes beyond yield.

The statistics, in plain English

A yield difference of 8.9 percentage points (interval 2.8 to 15.0) means roughly 9 more patients per 100 got a definitive tissue diagnosis. The moderate bleeding doubled, which matters if a centre cannot manage it, even though severe bleeding was no more frequent.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.